Latest Filings

Issuer Activity

Overview :: CVS Caremark Corporation (N:CVS) [?]
Business Focus: Drug Retailers Share on StockTwits
Recent Price for CVS
USD 73.74 0.00 (0.00%)
NYSE Delayed 15 minutes
Apr 17 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 76.36 19.67 N/A 87,641.39
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 55.66 1.5% 5,890,859  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 6:08am ET April 21st, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 3/14 Apr 2/14 Sussman Andrew Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -13,309  
Apr 3/14 Apr 2/14 Sussman Andrew Direct Ownership Common Stock S - Open market or private sale -5,901 $74.02
Apr 3/14 Apr 2/14 Sussman Andrew Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 5,901 $54.53
Apr 3/14 Apr 2/14 Sussman Andrew Direct Ownership Common Stock S - Open market or private sale -13,309 $74.02
Apr 3/14 Apr 2/14 Sussman Andrew Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 13,309 $45.07
Apr 3/14 Apr 2/14 Sussman Andrew Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -5,901  
Apr 3/14 Apr 2/14 Boratto Eva C Direct Ownership Common Stock S - Open market or private sale -4,425 $74.51
Apr 3/14 Apr 2/14 Boratto Eva C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 4,425 $54.53
Apr 3/14 Apr 2/14 Boratto Eva C Direct Ownership Common Stock S - Open market or private sale -6,029 $74.51
Apr 3/14 Apr 2/14 Boratto Eva C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 6,029 $34.96
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 6:08am ET April 21st, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 3/14 Apr 1/14 Bisaccia Lisa Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 33,569 $74.29
Apr 3/14 Apr 1/14 Bisaccia Lisa Direct Ownership Common Stock (restricted) A - Grant, award or other under Rule 16b-3(d) 5,384 $74.29
Apr 3/14 Apr 1/14 Bisaccia Lisa Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -3,086 $74.29
Apr 3/14 Apr 1/14 Roberts Jonathan C Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 73,433 $74.29
Apr 3/14 Apr 1/14 Roberts Jonathan C Direct Ownership Common Stock (restricted) A - Grant, award or other under Rule 16b-3(d) 11,778 $74.29
Apr 3/14 Apr 1/14 Roberts Jonathan C Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -2,026 $74.29
Apr 3/14 Apr 1/14 Merlo Larry J Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 335,697 $74.29
Apr 3/14 Apr 1/14 Merlo Larry J Direct Ownership Common Stock (restricted) A - Grant, award or other under Rule 16b-3(d) 53,843 $74.29
Apr 3/14 Apr 2/14 Sussman Andrew Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -13,309  
Apr 3/14 Apr 1/14 Sussman Andrew Direct Ownership Stock Option A - Grant, award or other under Rule 16b-3(d) 29,373 $74.29
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
 
See Regulatory Filings on SEC
Key People
David W. Dorman
Independent Chairman of the Board
Jonathan C. Roberts
Executive Vice President; President of CVS Caremark Pharmacy Services
Larry J. Merlo
President, Chief Executive Officer, Director
David M. Denton
Chief Financial Officer, Executive Vice President
Lisa G. Bisaccia
Chief Human Resource Officer, Senior Vice President
Thomas M. Moriarty
Executive Vice President, General Counsel
Troyen A. Brennan
Executive Vice President, Chief Medical Officer
Helena B. Foulkes
Executive Vice President, President of CVS/pharmacy
J. David Joyner
Executive Vice President
Per G. H. Lofberg
Executive Vice President
   
Company Contact
Address: One CVS Drive
WOONSOCKET RI 02895
Tel: 1-401-7703614
Website: info.cvscaremark.com
IR: phx.corporate-ir.net/phoenix.zhtml?c=99533&p=irol-irhome
Business Overview
CVS Caremark Corporation (CVS Caremark), together with its subsidiaries, is a pharmacy health care provider in the United States. CVS Caremark provides pharmacy services through its pharmacy benefit management (PBM), mail order and specialty pharmacy division, CVS Caremark Pharmacy Services; approximately 7,300 CVS/pharmacy retail stores; retail-based health clinic subsidiary, MinuteClinic, and its online retail pharmacy, CVS.com. The Company operates in three business segments: Pharmacy Services, Retail Pharmacy and Corporate. Its corporate segment provides management and administrative services. The Corporate segment consists of certain aspects of its executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments. In January 2014, Cvs Caremark Corporation completed the acquisition of Coram LLC, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc.
Financial Overview
For the fiscal year ended 31 December 2013, CVS Caremark Corporation revenues increased 3% to $126.76B. Net income before extraordinary items increased 19% to $4.6B. Revenues reflect Pharmacy Services Segment increase of 4% to $76.21B, Retail Pharmacy Segment increase of 3% to $65.62B, Retail Sales-Retail Pharmacy increase of 3% to $65.62B. Net income benefited from Retail Pharmacy Segment income increase of 11% to $6.27B.
Employees: 130,000 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $96,866M as of Dec 31, 2013
Annual revenue (TTM): $126,761M as of Dec 31, 2013
EBITDA (TTM): $9,907M as of Dec 31, 2013
Net annual income (TTM): $4,600M as of Dec 31, 2013
Free cash flow (TTM): $2,702M as of Dec 31, 2013
Net Debt Last Fiscal Year: $9,225M as of Dec 31, 2013
Shares outstanding: 1,188,518,985 as of Mar 13, 2014
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Cardinal Health (N:CAH)
Express Scripts Holding C (OQ:ESRX)
AmerisourceBergen (N:ABC)